Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12018679 | 0.96 | KDM4E (0.54) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL395752 | 0.89 | DRD2 (0.53) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL10911695 | 0.86 | KDM4E (0.55) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL10226464 | 0.86 | KDM4E (0.46) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL12324832 | 0.85 | MAPT (0.53) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL28217693 | 0.82 | MAPT (0.50) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL1670746 | 0.82 | MAPT (0.54) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL18089384 | 0.82 | MAPT (0.50) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL4541628 | 0.82 | CA12 (0.53) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL11924453 | 0.82 | KDM4E (0.43) | MAPTKDM4EGAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024130674-A1 | METHOD FOR PREPARING AMPHIPHILIC POLYMER | 深圳华大生命科学研究院 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024119122-A1 | CDK INHIBITORS AND METHODS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2023154426-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| WO-2023081759-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-11396503-B2 | Sulfonyl substituted bicyclic compound which acts as ROR inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-07-26 | — | — | US | disclosed |
| CN-111094267-B | Sulfonyl-substituted bicyclic compounds as ROR gamma inhibitors | 正大天晴药业集团股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2021222556-A1 | PI3K-α INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| WO-2011048148-A2 | GLYCOSIDE DERIVATIVE AND USES THEREOF | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011048112-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | disclosed |
| US-7645780-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-7544717-B2 | 2-amino- and 2-thio- substituted 1,3-diaminopropanes | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070212297-A1 | Amino methyl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-13 | — | — | US | disclosed |
| US-7244725-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-0173208-A1 | Tetrahydroquinolin-1-yl-carbonyl-imidazole derivatives | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318407-A1 | Inhibitors of protein kinases | SYK, BTK, JAK1 | MAPT 1178/4885KDM4E 1917/4885GAA 2777/4885 |
| US-11725000-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | MAPT 2304/4885KDM4E 1117/4885GAA 910/4885 |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | MAPT 4850/4885KDM4E 4200/4885GAA 3287/4885 |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | MAPT 3156/4885KDM4E 969/4885GAA 2341/4885 |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | SLC5A1, SLC5A2, SLC2A1 | MAPT 1112/4885KDM4E 2524/4885GAA 145/4885 |
| US-11396503-B2 | Sulfonyl substituted bicyclic compound which acts as ROR inhibitor | RORC, RORA, RORB | MAPT 3807/4885KDM4E 1812/4885GAA 2473/4885 |
| US-20070212297-A1 | Amino methyl imidazoles and related compounds as C5a receptor modulators | C5AR1, C3AR1, C5AR2 | MAPT 3843/4885KDM4E 486/4885GAA 4885/4885 |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | BACE1, BACE2, APP | MAPT 419/4885KDM4E 3339/4885GAA 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.